Co-administration of Rivaroxaban with Drugs That Share Its Elimination Pathways: Pharmacokinetic Effects in Healthy Subjects

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2013 Jan 12

PMID 23305158

Citations 162

Authors

Wolfgang Mueck

Dagmar Kubitza

Michael Becka

Affiliations

Soon will be listed here.

Abstract

Aims: The anticoagulant rivaroxaban is an oral, direct Factor Xa inhibitor for the management of thromboembolic disorders. Metabolism and excretion involve cytochrome P450 3A4 (CYP3A4) and 2J2 (CYP2J2), CYP-independent mechanisms, and P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp) (ABCG2).

Methods: The pharmacokinetic effects of substrates or inhibitors of CYP3A4, P-gp and Bcrp (ABCG2) on rivaroxaban were studied in healthy volunteers.

Results: Rivaroxaban did not interact with midazolam (CYP3A4 probe substrate). Exposure to rivaroxaban when co-administered with midazolam was slightly decreased by 11% (95% confidence interval [CI] -28%, 7%) compared with rivaroxaban alone. The following drugs moderately affected rivaroxaban exposure, but not to a clinically relevant extent: erythromycin (moderate CYP3A4/P-gp inhibitor; 34% increase [95% CI 23%, 46%]), clarithromycin (strong CYP3A4/moderate P-gp inhibitor; 54% increase [95% CI 44%, 64%]) and fluconazole (moderate CYP3A4, possible Bcrp [ABCG2] inhibitor; 42% increase [95% CI 29%, 56%]). A significant increase in rivaroxaban exposure was demonstrated with the strong CYP3A4, P-gp/Bcrp (ABCG2) inhibitors (and potential CYP2J2 inhibitors) ketoconazole (158% increase [95% CI 136%, 182%] for a 400 mg once daily dose) and ritonavir (153% increase [95% CI 134%, 174%]).

Conclusions: Results suggest that rivaroxaban may be co-administered with CYP3A4 and/or P-gp substrates/moderate inhibitors, but not with strong combined CYP3A4, P-gp and Bcrp (ABCG2) inhibitors (mainly comprising azole-antimycotics, apart from fluconazole, and HIV protease inhibitors), which are multi-pathway inhibitors of rivaroxaban clearance and elimination.

Citing Articles

Comparative Bleeding Risk in Older Patients With HIV and Atrial Fibrillation Receiving Oral Anticoagulants.

Quinlan C, Avorn J, Kesselheim A, Singer D, Zhang Y, Cervone A JAMA Intern Med. 2025; .

PMID: 39992678 PMC: 11851300. DOI: 10.1001/jamainternmed.2024.8335.

Effect of drug interactions with apixaban on clinical outcomes in cancer patients with venous thromboembolism.

Svalastoga M, Larsen T, Brekke J, Enden T, Froen H, Garresori H Front Oncol. 2025; 15:1520725.

PMID: 39931081 PMC: 11807833. DOI: 10.3389/fonc.2025.1520725.

Evaluation of Drug-Drug Interactions Between Clarithromycin and Direct Oral Anticoagulants Using Physiologically Based Pharmacokinetic Models.

Yang Z, Qu Y, Sun Y, Pan J, Zhou T, Yu Y Pharmaceutics. 2024; 16(11).

PMID: 39598572 PMC: 11597346. DOI: 10.3390/pharmaceutics16111449.

Key Factors for Improving Predictive Accuracy and Avoiding Overparameterization of the PBPK Absorption Model in Food Effect Studies of Weakly Basic Water-Insoluble Compounds in Immediate Release Formulations.

Zhang M, Zhang S, Wang L, Zhang Z, Hu Q, Liu D Pharmaceutics. 2024; 16(10).

PMID: 39458653 PMC: 11511194. DOI: 10.3390/pharmaceutics16101324.

Application of a Novel UPLC-MS/MS Method for Analysis of Rivaroxaban Concentrations in Dried Blood Spot and Plasma Samples Collected from Patients with Venous Thrombosis.

Pawlak K, Kruszyna L, Miecznikowska M, Karazniewicz-Lada M Molecules. 2024; 29(17).

PMID: 39274988 PMC: 11397208. DOI: 10.3390/molecules29174140.

References

Wang J, Wen X, Backman J, Taavitsainen P, Neuvonen P, Kivisto K . Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacol Toxicol. 1999; 85(4):157-61. DOI: 10.1111/j.1600-0773.1999.tb00085.x. View

Cooper K, Martin P, Dane A, Warwick M, Raza A, Schneck D . The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol. 2003; 59(1):51-6. DOI: 10.1007/s00228-003-0573-7. View

Kim R, Wandel C, Leake B, Cvetkovic M, Fromm M, Dempsey P . Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999; 16(3):408-14. DOI: 10.1023/a:1018877803319. View

Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D . Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2009; 37(5):1056-64. DOI: 10.1124/dmd.108.025569. View

Holtzman C, Wiggins B, Spinler S . Role of P-glycoprotein in statin drug interactions. Pharmacotherapy. 2006; 26(11):1601-7. DOI: 10.1592/phco.26.11.1601. View

Mega J, Braunwald E, Wiviott S, Bassand J, Bhatt D, Bode C . Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2011; 366(1):9-19. DOI: 10.1056/NEJMoa1112277. View

von Moltke L, Greenblatt D, Grassi J, Granda B, Duan S, Fogelman S . Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol. 1998; 38(2):106-11. DOI: 10.1002/j.1552-4604.1998.tb04398.x. View

Kumar A, Cannon C . Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention. J Interv Cardiol. 2007; 20(6):447-57. DOI: 10.1111/j.1540-8183.2007.00298.x. View

Buller H, Prins M, Lensin A, Decousus H, Jacobson B, Minar E . Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366(14):1287-97. DOI: 10.1056/NEJMoa1113572. View

10.

Luurila H, Olkkola K, Neuvonen P . Interaction between erythromycin and nitrazepam in healthy volunteers. Pharmacol Toxicol. 1995; 76(4):255-8. DOI: 10.1111/j.1600-0773.1995.tb00139.x. View

11.

Gupta A, Zhang Y, Unadkat J, Mao Q . HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2004; 310(1):334-41. DOI: 10.1124/jpet.104.065342. View

12.

Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G . Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005; 78(4):412-21. DOI: 10.1016/j.clpt.2005.06.011. View

13.

Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer K . In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005; 3(3):514-21. DOI: 10.1111/j.1538-7836.2005.01166.x. View

14.

Turpie A, Lassen M, Eriksson B, Gent M, Berkowitz S, Misselwitz F . Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost. 2010; 105(3):444-53. DOI: 10.1160/TH10-09-0601. View

15.

Kronbach T, Mathys D, Umeno M, Gonzalez F, Meyer U . Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol. 1989; 36(1):89-96. View

16.

Bauersachs R, Berkowitz S, Brenner B, Buller H, Decousus H, Gallus A . Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26):2499-510. DOI: 10.1056/NEJMoa1007903. View

17.

Biemond B, Perzborn E, Friederich P, Levi M, Buetehorn U, Buller H . Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor. Thromb Haemost. 2007; 97(3):471-7. View

18.

Gupta A, Unadkat J, Mao Q . Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J Pharm Sci. 2007; 96(12):3226-35. DOI: 10.1002/jps.20963. View

19.

Mueck W, Lensing A, Agnelli G, Decousus H, Prandoni P, Misselwitz F . Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011; 50(10):675-86. DOI: 10.2165/11595320-000000000-00000. View

20.

Mao Q, Unadkat J . Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005; 7(1):E118-33. PMC: 2751502. DOI: 10.1208/aapsj070112. View